Nodify Lung
Commercial- Indications
- Lung cancer risk assessment
Company intelligence / Profile preview
Biodesix has five Medicare-covered, non-invasive blood-based diagnostic tests for lung disease and lung cancer management. These include the Nodify Lung® strategy for nodule risk assessment and the IQLung™ strategy for treatment guidance in lung cancer. The company’s tests are used to expedite diagnosis and guide personalized treatment decisions with rapid turnaround times of 2–3 business days. Clinical adoption continues to grow rapidly, as evidenced by strong revenue growth[4][5][7].
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biodesix.